Quality control report of Heart Valve Center in 2024
10.3969/j.issn.1004-8812.2025.11.002
- VernacularTitle:心脏瓣膜病介入中心年度报告(2024)
- Author:
Da-xin ZHOU
;
Yong-jian WU
;
Jian-an WANG
;
Jun-bo GE
- Collective Name:China Heart House,Heart Valve Center,Professional Committee of National Clinical Research Center for Interventional Medicine
- Publication Type:Journal Article
- Keywords:
Heart Valve Centers;
National Transcatheter Valve Therapeutics Registry;
Consensus development conference
- From:
Chinese Journal of Interventional Cardiology
2025;33(11):614-619
- CountryChina
- Language:Chinese
-
Abstract:
With the aging of the population,the disease burden of heart valve disease in China has significantly increased.In recent years,the interventional treatment for heart valve disease has flourished,among which transcatheter aortic valve replacement(TAVR)has become the first-line treatment for elderly patients with aortic valve stenosis.China started relatively late in the field of interventional treatment for heart valve disease.The construction of heart valve centers helps to standardize the diagnosis and interventional treatment of heart valve disease in China and improve the management of prognosis for patients.Up to December 2024,a total of 453 centers have participated in the construction of heart valve centers,including 100 construction centers and 40 certification centers.The National Transcatheter Valve Therapeutics Registry(NTCVR)database has reported a total of 28 594 cases,with approximately 50％of Chinese TAVR cases recorded in NTCVR database.The construction of the heart valve centers has shown initial results,significantly optimizing the process of diagnosis and treatment of heart valve disease and improving the prognosis.At present,there are still many shortcomings in the construction of heart valve centers.For example,the follow-up rate of patients after discharge is low,and long-term management after discharge needs to be further improved.There is still a gap in some indicators between construction centers and certification centers,and the promotion of high-quality management of interventional treatment of heart valve disease in China is still a long way to go.
